Meeting Banner
Abstract #1547

Liver metabolomic investigation of lentiviral targeting of GDPD5 and GDPD6 for breast cancer treatment in a preclinical model

Kanchan Sonkar1, Marina Stukova2, Caitlin M. Tressler1, Balaji Krishnamachary1, Zaver M. Bhujwalla1,3, and Kristine Glunde1,3

1The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, United States, 2San Juan Bautista School of Medicine, Caguas, PR, United States, 3The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, United States

High-resolution 1H MRS is a powerful technique for metabolomics studies of tissues, cells, and body fluids. Here we have used this technique to explore metabolomic changes in the livers of mice that have been treated with lentiviral particles that silence either of the two glycerophosphodiesterase GDPD5 (GDPD5-shRNA) or GDPD6 (GDPD6-shRNA). We systemically administered lentiviral shRNA in mice with orthotopic breast tumor xenografts. We identified distinct increases in leucine, valine, glutathione, creatine, glucose, tyrosine, and histidine in the GDPD5-shRNA treated group, whereas cholesterol, isoleucine, beta-hydroxy butyrate, alanine, glutamate, glutamine, aspartate, fumerate, phenylalanine, and formate were elevated in the GDPD6-shRNA treated group.

This abstract and the presentation materials are available to members only; a login is required.

Join Here